I'm not really on the inside looking out,Mark...
I'm just surprised at the lack of clinical information. Like Peter Lynch stated in his book, "Beating Wall Street", one can find investment opportunities in your own back yard. My back yard is pharmaceuticals.
I'm the pharmacy director of a 350 bed hospital in Canada. I have companies coming to see me all the time, asking for the hospital to use particular drugs. Granted, this is after NOC (notice of compliance) has been issued by Health Canada, however, I do demand certain information from the companies...data supporting efficacy, data outlining potential adverse effects, comparative data against other agents used for the same purposes, and, more and more, pharmacoeconomic data to support that the product is cost-effective.
Where I'm scratching my head is, for a company that has completed phase III clinical trials, its information is surprisingly sketchy...
...maybe I'm just too paranoid...
I also have not heard about SYB...will have to check it out...
...also am much more optimistic now about Hemosol (HML.T)...starting phase III trials for their blood substitute product...if it passes...this company could be HUGE!
All the best,
JEff
|
